This 68-week study followed 1,961 adults with obesity or overweight who did not have diabetes
Foundayo (orforglipron): An oral GLP-1 medication, distinct for its flexibility, as it can be taken anytime without food or water restrictions
The rapid growth of compounded GLP-1 receptor agonist prescriptions, including formulations of semaglutide and tirzepatide dispensed directly to patients, has placed new pressure on compounding pharmacies to master one of the most demanding areas of pharmaceutical logistics: cold chain shipping for temperature-sensitive medications
As we did not observe any discontinuation of treatment during the study period, it remains unclear whether pwIIH successfully treated with GLP-1-RAs sustain their weight loss, or a yo-yo effect occurs [44], which would pose an increased risk for a disease relapse
People with type 2 diabetes Researchers with type 2 diabetes typically see slower weight loss on semaglutide compared to non-diabetic individuals